Phase I to II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Patients With Advanced Chronic Lymphocytic Leukemia The literature review identified one published ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback